Trial Search Results
Phase II Trial of Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)
A research study using a method of treating lung cancer with focused radiation called Stereotactic Ablative Radiotherapy (SABR). The purpose of this study is to evaluate the effectiveness of individualizing the dose of radiation used to treat lung tumors with SABR based on tumor-specific factors.
Stanford is currently accepting patients for this trial.
- Diagnostic Test: PET Scan
- Diagnostic Test: CT Scan
- Radiation: SABR
- Limited primary or metastatic lung tumors with no evidence of uncontrolled
- Up to 4 lesions may be included, with none larger than 5 cm if there are more than
one, or up to 7 cm if there is a single tumor
- Both peripheral and central tumors are accepted for this trial.
- Age > 18 years old
- Both men and women and members of all races and ethnic groups are eligible for this
- Note: Patients may be enrolled more than once (e.g. for a new tumor)
- Evidence of uncontrolled extrathoracic metastases
- Contraindication to receiving radiotherapy.
- Contraindication to receiving radiotherapy
- Age < 18 years old. Children are excluded because lung malignancies rarely occur in
this age group. Furthermore, treatment requires a great deal of patient cooperation
including the ability to lie still for several hours in an isolated room.
- Pregnant and breastfeeding women are excluded; as well as women of child-bearing
potential who are unwilling or unable to use an acceptable method of birth control
(hormonal or barrier method of birth control; abstinence) to avoid pregnancy for the
duration of the study. Male subjects must also agree to use effective contraception
for the same period as above. Should a woman become pregnant or suspect she is
pregnant while participating in this study, she should inform her treating physician
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study